ArticleClinical rheumatology2026
The clinical characteristics and risk factors of pulmonary arterial hypertension in primary Sjögren disease: a single-center retrospective study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo summarize clinical characteristics and explore risk factors of pulmonary arterial hypertension (PAH) in patients with primary Sjögren disease (pSjD).
methodsWe retrospectively collected the clinical data of 190 pSjD inpatients, who were stratified into groups with PAH (pSjD-PAH) and without PAH (pSjD-non-PAH). The differences of clinical manifestations, laboratory tests, EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score, and transthoracic echocardiography (TTE) parameters between two groups were compared. A subgroup analysis was performed in pSjD-PAH patients according to pericardial effusion (PE) status.
resultsA total of 32 pSjD patients with PAH and 158 pSjD patients without PAH were analyzed. Patients in the pSjD-PAH group were older, with a higher incidence of mild interstitial lung disease (ILD) and diabetes (p < 0.05). They also exhibited higher levels of leukocytes, red blood cell distribution width (RDW), total bilirubin (TBIL), γ-glutamyltransferase (γ-GT), lactate dehydrogenase (LDH), and uric acid (UA) (p < 0.05). Logistic regression analysis identified mild ILD, age, and TBIL as independent risk factors for PAH in patients with pSjD. A predictive model was constructed and internally validated. In the subgroup analysis, ESSDAI score was comparable (p > 0.05), whereas values of pulmonary artery systolic pressure (PASP), pulmonary artery pressure (PA), and right atrial diameter (RAD) were higher in the PE-positive subgroup (p < 0.05).
conclusionsMild ILD, age, and TBIL are identified as independent risk factors for PAH in patients with pSjD. PE formation in pSjD-PAH patients may be associated with elevated right-sided heart pressure. Key Points • Pulmonary arterial hypertension (PAH) is a common cause of death in patients with primary Sjögren disease (pSjD), and relevant studies remain limited. • PSjD patients with PAH are more likely to have pericardial effusion (PE), which may result from elevated right-sided heart pressure and subsequent venous return obstruction. • Several risk factors were identified to enable early identification of pSjD-PAH patients.
Indexed as
Identifiers
42446617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.